Le Lézard
Classified in: Covid-19 virus

Global Cardiac POC Testing Devices Market Report 2022: Rising Incidence, Mounting Economic and Social Burden of Cardiovascular Disease to Drive Growth - ResearchAndMarkets.com


The "Cardiac POC Testing Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Cardiac POC Testing Devices Market to Reach US$1.7 Billion by the Year 2026

Cardiac POC testing devices help in assessing cholesterol and blood glucose levels. Cardiac POC assay test kits deliver accurate results promptly and cost-effectively with standardization for minimizing operational errors. Cardiac POC diagnostic kits are finding increasing application in emerging countries with remote geographical areas, dearth of skilled medical personnel and testing laboratory infrastructure.

The increasing adoption of sensitivity and premium-priced POC Troponin tests is contributing to the growth of the global market. The growing move towards value-based and efficient healthcare service delivery against the backdrop of stringent budgets is boosting the prospects for POC Cardiac testing market. Moreover, the majority of medical professionals opt of POC cardiac testing to quickly monitor the condition of patients experiencing chest pain or other heart ailment symptoms in emergency care environments. The global phenomenon of the burgeoning aging populace is driving demand for POC test kits for use in home healthcare and old age homes.

Growing patient awareness and the increasing availability of over the counter POC tests is a major factor propelling the POC tests market. At a time when the global healthcare industry is transitioning from disease treatment to disease prevention through increased involvement with patients, POC diagnostic kits are playing an instrumental role in reducing the risk of occurrence and the intensity of prevailing diseases by facilitating prompt diagnosis and earlier clinical intervention.

Amid the COVID-19 crisis, the global market for Cardiac POC Testing Devices estimated at US$1.4 Billion in the year 2022, is projected to reach a revised size of US$1.7 Billion by 2026, growing at a CAGR of 5.8% over the analysis period.

The U.S. Market is Estimated at $531.3 Million in 2022, While China is Forecast to Reach $192.6 Million by 2026

The Cardiac POC Testing Devices market in the U.S. is estimated at US$531.3 Million in the year 2022. The country currently accounts for a 37.36% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$192.6 Million in the year 2026 trailing a CAGR of 7.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR while Rest of European market (as defined in the study) will reach US$204.7 Million by the end of the analysis period. The United States represents the largest market, driven by high prevalence of cardiovascular diseases, higher levels of physician and patient awareness, favorable government policies, and high usage of cardiac tests. The Asia Pacific region is also growing steadily on account of the increasing awareness about cardiac diagnosis and treatment as well as rising healthcare expenditure.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/nofjqa


These press releases may also interest you

at 18:00
Voxtur Analytics Corp. , a North American technology company creating a more transparent and accessible real estate lending ecosystem, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market...

at 18:00
On April 19, 2024, the board of directors of Portland General Electric Company declared a quarterly common stock dividend of $0.50 per share, representing an increase of 5.3%, or $0.10 per share, on an annualized basis. The company's dividend is...

at 17:52
Adyton Resources Corporation  ("Adyton" or the "Company") announces it has closed its previously announced non-brokered private placement offering, pursuant to which it has issued 50,000,000 common shares of the Company ("Shares") at a price of...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
Lion Group Holding Ltd. ("Lion" or "the Company") , the operator of an all-in-one trading platform that offers a wide spectrum of products and services, today announced that on April 18, 2024, it received a delinquency notification letter from the...

at 16:30
Cosmos Health Inc. ("Cosmos Health" or the "Company'') , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor...



News published on and distributed by: